Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Recalls & Court Actions: March 28, 1990

Executive Summary

CLASS II -- EPINEPHRINE MIST 1/2 ounce (15 cc) size, an OTC inhalation aerosol bronchodilator for the relief of bronchial asthma under the Barre-National, Eckerd Drug, Laverdiere's Super Drug, Longs Drug Stores, Peoples Drug Stores, Perry Distributing Inc., Pic N Save Drugs, Revco, Rite Aid, Rugby Labs Inc., Thrift Drug Company, Thrifty Corporation, and Walgreen Co. labels. Code: 82003, 82004, 82060, 82127, 82128, 82175, 82176, 82282, 82284, 82359, 82521, 82622, 82623, 82624, 82625, 92014, 92135, 92136, 92218, 92219, 92220, 92295, 92340, 92341. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letters Dec. 4 and 8, 1989. Firm-initiated recall ongoing. Distribution: Nationwide. 1,126,392 units were distributed. Reason: Potency not assured through expiration date. CLASS II -- INDOMETHACIN CAPSULES, USP 25 mg and 50 mg, an Rx non-steroidal anti-inflammatory packaged in bottles of 100, 500 and 1,000 capsules under the Bioline, Goldline, Schein, and Superpharm labels. All lots. Manufacturer: Superpharm Corporation, Bayshore, New York. Recalled by: Manufacturer, by letter Feb. 1, 1990. Firm-initiated recall ongoing. Distribution: New York, California, Connecticut, Florida, Ohio, Texas. 4,200,000/25 ml bottles and 1,700,000/50 ml bottles were distributed. Reason: Lack of assurance of bioequivalency and Abbreviated New Drug Application discrepancies. CLASS II -- OTC ANTACID ORAL SUSPENSION With 200 mg magnesium hydroxide and 225 mg aluminum hydroxide in 12 ounce bottles, used for the relief of heart burn, acid indigestion, sour stomach and upset stomach, under the Geneva Generics and RIJ Pharmaceutical labels. Lot #90609. Manufacturer: RIJ Pharmaceutical Corporation, Chester, New York. Recalled by: Manufacturer, by telephone Feb. 7, 1990. Firm- initiated recall ongoing. Distribution: Tennessee, Georgia, Massachusetts, Rhode Island. Firm estimates less than 1 percent remains on market. Reason: Bacterial contamination. CLASS II -- TRIAMTERENE/HYDROCHLOROTHIAZIDE TABLETS 75 mg/50 mg, in bottles of 100, 500, and 1,000, an Rx diuretic used for the treatment of hypertension, under the American Therapeutics, Best Generics, Bioline Laboratories, Goldline Laboratories, Harbor Pharmaceutical and Kaiser Foundation Hospital labels. Lot No.: 805134 exp. 5/90; Lot No.: 812380, exp. 12/90; Lot No.: 810288, exp. 10/90; Lot No.: 812381, exp. 12/90; Lot No.: 810289, exp. 10/90; Lot No.: 812388, exp. 12/90; Lot No.: 811326, exp. 11/90; Lot No.: 901031, exp. 1/91; Lot No.: 812359, exp. 12/90; Lot No.: 901032, exp. 1/91; Lot No.: 812360, exp. 12/90; Lot No.: 903062, exp. 3/91; Lot No.: 812361, exp. 12/90; Lot No.: 903063, exp. 3/91; Lot No.: 812362, exp. 12/90; Lot No.: 903064, exp. 3/91. Manufacturer: American Therapeutucs, Inc., Bohemia, New York. Recalled by: Manufacturer, by letter Feb. 6-8, 1990. Firm-initiated recall ongoing. Distribution: California, Connecticut, Florida, Georgia, Kentucky, Louisiana, Massachusetts, Maryland, Missouri, Mississippi, North Carolina, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Virginia. 16 lots each consisting of 1,000,000 tablets were distributed; firm estimates 1.6 million tablets remain on the market. Reason: Product failed dissolution testing. CLASS III -- INSULIN AND SODIUM CHLORIDE INJECTION, USP In 50 ml vials, an Rx drug administered intravenously as a sterile, non-pyrogenic solution and used as a diagnostic agent to measure kidney glomerular filtration. Lot 58803 EXP 3/90. Manufacturer: Taylor Pharmacal Company, Decatur, Illinois. Recalled by: Iso-Tex Diagnostics, Inc., Friendswood, Texas, by telephone Feb. 20-21, 1990. Firm-initiated recall ongoing. Distribution: Nationwide, Canada. 2,059 vials were distributed; firm estimates 240 vials remain on market. Reason: Free fructose exceeds USP limit. CLASS III -- LARIAM (MEFLOQUINE HYDROCHLORIDE) TABLETS 250 mg, in unit dose aluminum foil strips in cartons containing 25 tablets, a newly approved Rx antimalarial agent. Code: 0001 EXP 9/1/92. Manufacturer: F. Hoffmann-LaRoche & Co., Ltd., Basle, Switzerland. Recalled by: Roche Laboratories, Nutley, New Jersey, by telephone Feb. 28, 1990 and March 1-2, 1990 followed by letter March 3 and 6, 1990. Firm-initiated recall ongoing. Distribution: Nationwide. 1,859 (25 unit dose foil packs each) were distributed. Reason: Packaging defect -- Some unit dose blisters contain two tablets instead of one tablet. CLASS III -- MOISTUREL CREAM In 4 ounce and 16 ounce jars, an OTC drug to be applied to the skin for generalized dry skin. Lot numbers 95A011 through 95A056 and 95B001 through 95B046. Manufacturer: Westwood Pharmaceuticals, Inc., Buffalo, New York. Recalled by: Manufacturer, by telephone Jan. 30, 1990 followed by letter. Firm-initiated recall ongoing. Distribution: Nationwide. 549,036 jars were distributed; firm estimates 60,000 jars remain on market. Reason: Preservative system may not be effective during use of product.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel